
News|Videos|December 9, 2020
The Most Interesting Results from the RESET Clinical Trial
In an interview with Pharmacy Times, Helen Thackray, MD, reveals what finding she believes was the most interesting after analyzing the results of the RESET clinical trial, which covers the early initiation with rivipansel for acute vaso-occulusive crisis in sickle cell disease.
Advertisement
In an interview with Pharmacy Times, Helen Thackray, MD, reveals what finding she believes was the most interesting after analyzing the results of the RESET clinical trial, which covers the early initiation with rivipansel for acute vaso-occulusive crisis in sickle cell disease. This study was presented at the 62nd ASH Annual Meeting and Exposition.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
Single-Center Experience With Vorasidenib in Patients With Grade 3 or 4 IDH-Mutant Gliomas
2
McKesson ideaShare 2026: Recapping Key Insights from Denver
3
The Human Element: Building Relationships and Empathy in a Busy Pharmacy
4
Personalized Cancer Vaccines and Immunotherapy Advance Melanoma Care
5




















































































































